Increased metabolic activity in the spinal cord of patients with long-standing Lhermitte's sign

Strahlentherapie und Onkologie

Volumn 179, Issue 10, 2003, Pages 690-693

  Ésik, Olga ^a,b   Csere, Tibor ^f   Stefanits, Klára ^f   Szakáll Jr , Szabolcs ^f   Lengyel, Zsolt ^f   Sáfrány, Géza ^c   Vönöczky, Katalin ^b   Lengyel, Erzsébet ^b   Olajos, Judit ^d   Bajzik, Gábor ^f   Trón, Lajos ^e  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^c National Research Institute for Radiobiology and Radiohygiene Budapest   (Hungary)

^d Josa Andras County Hospital   (Hungary)

^e INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^f NONE

Author keywords

11C methionine; 18F fluorodeoxyglucose; 15O butanol; Functional recovery; Nasopharyngeal carcinoma; Permanent Lhermitte's sign; Positron emission tomography; Radiation myelopathy; Radiosensitivity

Indexed keywords

BUTANOL; FLUORODEOXYGLUCOSE F 18; METHIONINE C 11;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; CERVICAL SPINE; CLONOGENIC ASSAY; FEMALE; FIBROBLAST; HUMAN; MALE; METABOLISM; NASOPHARYNX CANCER; PERFUSION; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIOSENSITIVITY; SPINAL CORD; SPINAL CORD DISEASE;

ADULT; FEMALE; FIBROBLASTS; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHIONINE; NASOPHARYNGEAL NEOPLASMS; RADIATION INJURIES; RADIATION TOLERANCE; RADIOPHARMACEUTICALS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SPINAL CORD; SPINAL CORD DISEASES; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 17544384924     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-003-1115-z     Document Type: Article

References (36)

1. Boden G. Radiation myelitis of the cervical spinal cord. Br J Radiol 1948; 21:464-9.
2. Carmel RJ, Kaplan HS. Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications. Cancer 1976;37:2813-25.
3. 18F-2-deoxyglucose in normal and pathological cases. J Comput Assist Tomogr 1983;7:937-45.
4. Dynes JB, Smedal MI. Radiation myelitis. Am J Roentgenol 1960;83:78-87.
5. Elkind MM, Whitmore GF. The radiobiology of cultured mammalian cells. New York: Gordon & Breach, 1967.
6. Ésik O, Emri M, Csornai M, et al. Radiation myelopathy with partial functional recovery: PET evidence of long-term increased metabolic activity of the spinal cord. J Neurol Sci 1999;163:39-43.
7. Fein DA, Marcus RB Jr, Parsons JT, et al. Lhermitte's sign: incidence and treatment variables influencing risk after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys 1993;27:1029-33.
8. Felts PA, Baker TA, Smith KJ. Conduction in segmentally demyelinated mammalian central axons. J Neurosci 1997;17:7267-77.
9. Freshney RI. Culture of animal cells: a manual of basic techniques. New York: Liss, 1987:113-5.
10. Glanzmann C, Aberle HG, Horst W. The risk of chronic progressive radiation myelopathy. Strahlentherapie 1976;152:363-72.
11. 11C-methionine. J Comput Assist Tomogr 1990;14:297-9.
12. Jellinger K, Sturm KW. Delayed radiation myelopathy in man. Report of twelve necropsy cases. J Neurol Sci 1971;14:389-408.
13. Jones A. Transient radiation myelopathy (with reference to Lhermitte's sign of electrical paraesthesia). Br J Radiol 1964;37:727-44.
14. Kamoto Y, Sadato N, Yonekura Y, et al. Visualization of the cervical spinal cord with FDG and high-resolution PET. J Comput Assist Tomogr 1998;22:487-91.
15. 18F)-FDG positron emission tomography after neoadjuvant radiation treatment of mouth carcinoma. Strahlenther Onkol 2001;177:145-52.
16. Lang O, Bihl H, Hultenschmidt B, et al. Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease. Strahlenther Onkol 2001;177:138-44.
17. Lewanski CR, Sinclair JA, Stewart JS. Lhermitte's sign following head and neck radiotherapy. Clin Oncol (R Coll Radiol) 2000;12:98-103.
18. Meltzer CC, Townsend DW, Kottapally S, et al. FDG imaging of spinal cord primitive neuroectodermal tumor. J Nucl Med 1998;39:2121-7.
19. National Cancer Institute. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. Bethesda, MD, USA: National Cancer Institute, 1997 (http://ctep.info.nih.gov).
20. Palmer JJ. Radiation myelopathy. Brain 1972;95:109-22.
21. Rades D, Kuhnlel G, Wildfang I, et al. The value of positron emission tomography (PET) in the treatment of patients with cancer of unknown primary (CUP). Strahlenther Onkol 2001;177:525-9.
22. Rahn AN. Baum RP, Adamietz IA, et al. Value of [18F] fluorodeoxyglucose positron emission tomography in radiotherapy planning of head-neck tumors. Strahlenther Onkol 1998;174:358-64.
23. Roland PE. Brain activation. New York: Wiley-Liss, 1993:469-504.
24. 11C-methyl)-L-methionine. Neuroradiology 1996;38:53-5.
25. Schultheiss TE, Kun LE, Ang KK, et al. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 1995;31:1093-112.
26. Schultheiss TE, Stephens LC, Maor MH. Analysis of the histopathology of radiation myelopathy. Int J Radiat Oncol Biol Phys 1988;14:27-32.
27. Ševčikova L, Bolješiková E, Chorváth M, et al. Long-term (15 years) results of extended field radiotherapy in Hodgkin's disease. Neoplasma 2000;47:253-6.
28. Solheim ØP. Radiation injury of the spinal cord. Acta Radiol Ther Phys Biol 1971;10:474-80.
29. Thornton AF, Zimberg SH, Greenberg HS, et al. Protracted Lhermitte's sign following head and neck irradiation. Arch Otolaryngol Head Neck Surg 1991;117:1300-3.
30. Waxman SG. Demyelinating diseases - new pathological insights, new therapeutic targets. N Eng J Med 1998;338:323-5.
31. Weber WA, Avril N, Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 1999;175:356-73.
32. Wilmshurst JM, Barrington SF, Pritchard D, et al. Positron emission tomography in imaging spinal cord tumors. J Child Neurol 2000;15:465-72.
33. Woesler B, Kuwert T, Probst-Cousin S, et al. Spinal metastases of a high grade astrocytoma visualized with FDG-PET. Clin Nucl Med 1997;22:863-4.
34. Wong CS, van Dyk J, Milosevic M, et al. Radiation myelopathy following single courses of radiotherapy and retreatment. Int J Radiat Oncol Biol Phys 1994;30:575-81.
35. Word JA, Kalokhe UP, Aran BS, et al. Transient radiation myelopathy (Lhermitte's sign) in patients with Hodgkin's disease treated by mantle irradiation. Int J Radiat Oncol Biol Phys 1980;6:1731-3.
36. Zhou PK, Sproston ARM, Marples B, et al. The radiosensitivity of human fibroblast cell lines correlates with residual levels of DNA double-strand breaks. Radiother Oncol 1998;47:271-6.